TMCnet News
IQVIA to Build Clinically-Focused Tech Solutions Suite for Life Sciences on Salesforce Health CloudIQVIA (NYSE: IQV) today announced the expansion of its alliance with Salesforce, the global leader in CRM and provider of Software as a Service (SaaS (News - Alert)) solutions, to build a clinical solution for life sciences on Salesforce Health Cloud. IQVIA's suite of clinical technology solutions can speed clinical trials, while reducing patient burden, with the ultimate goal of advancing human health. "We are proud of this strategic collaboration with IQVIA's technology capabilities and the important role that Salesforce will have in accelerating clinical innovation," said Tyler Prince, EVP, Industries and Partners, Salesforce. "This is the next step in the Salesforce and IQVIA commitment to accelerate life sciences products more quickly through the entire product lifecycle." The clinical suite, which leverages IQVIA's deep life sciences expertise, includes both SaaS and technology-enabled services that will automate study processes, drive R&D insights from artificial intelligence and machine learning, and strengthen connections between patients and clinicians. The general components of this IQVIA expansion will include:
The suite of clinical solutions will be designed to accelerate research and trial safety, in addition to protecting patient privacy while boosting patient participation, adherence and convenience throughout the study. "We are excited to build a suite of applications that will enable an uninterrupted flow of study information and results, while connecting clinical, regulatory, and compliance content to the Orchestrated Customer Engagement solution on a common Salesforce platform," said Tal Rosenberg, senior vice president, Global Technology Solutions (News - Alert) at IQVIA. While terms of the agreement have not been disclosed, it is a multi-year alliance that will operate on a global scale. Salesforce, Health Cloud and others are among the trademarks of salesforce.com, inc. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science - leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science - to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps its customers drive human health outcomes forward. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Click here to subscribe to Mobile Alerts for IQVIA. View source version on businesswire.com: https://www.businesswire.com/news/home/20180920005128/en/ |